# A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

> **NCT03602859** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Tesaro, Inc.** · enrollment: 1400 (actual)

## Conditions studied

- Ovarian Neoplasms
- Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab (TSR-042)
- **DRUG:** Standard of care
- **DRUG:** Dostarlimab-Placebo
- **DRUG:** Niraparib-Placebo

## Key facts

- **NCT ID:** NCT03602859
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-11
- **Primary completion:** 2024-10-31
- **Final completion:** 2029-04-30
- **Target enrollment:** 1400 (ACTUAL)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602859, "A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03602859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*